Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 15, 2015 01:20 ET | Source: Basilea Pharmaceutica Ltd.

Basilea signs exclusive distribution agreement for Zevtera(r) (ceftobiprole medocaril) in the Middle East and North Africa with Hikma Pharmaceuticals LLC

Hikma to commercialize antibiotic Zevtera® in the Middle East and North Africa (MENA) region Agreement expands the global availability of Zevtera® BASEL, Switzerland, Oct. 15,...
October 12, 2015 01:18 ET | Source: Basilea Pharmaceutica Ltd.

Basilea announces that Health Canada approved ZEVTERA(r) for the treatment of bacterial lung infections

BASEL, Switzerland, Oct. 12, 2015 (GLOBE NEWSWIRE) -- Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that Health Canada has approved ZEVTERA® (ceftobiprole medocaril) for the treatment of...
August 28, 2015 01:18 ET | Source: Basilea Pharmaceutica Ltd.

Basilea's Chief Technology Officer Dr. Ingrid Heinze-Krauss to retire and Dr. Gunter Ditzinger named as successor

BASEL, Switzerland, Aug. 28, 2015 (GLOBE NEWSWIRE) -- Basilea Pharmaceutica Ltd. (SIX: BSLN) reports today that Dr. Ingrid Heinze-Krauss will retire after 15 years with the company. Basilea named Dr....
August 14, 2015 01:19 ET | Source: Basilea Pharmaceutica Ltd.

Basilea reports 2015 half-year results - Major milestones achieved for CRESEMBA(R) and Zevtera(R)

Antifungal CRESEMBA® (isavuconazole) received U.S. approval and is recommended for approval in the European Union Antibiotic Zevtera®/Mabelio® (ceftobiprole medocaril) launched...
July 24, 2015 07:48 ET | Source: Basilea Pharmaceutica Ltd.

Basilea announces that CHMP recommends approval of isavuconazole (CRESEMBA(R)) as a treatment for invasive aspergillosis and mucormycosis in the European Union

BASEL, Switzerland, July 24, 2015 (GLOBE NEWSWIRE) -- Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines...
February 17, 2015 01:19 ET | Source: Basilea Pharmaceutica Ltd.

Basilea reports solid 2014 full-year results, preparing the ground for commercialization of Zevtera(R) in Europe

Antifungal isavuconazole U.S. NDA and European MAA submissions under regulatory review - decisions expected in Q1 2015 in the U.S. and Q4 2015 in the EU First commercial launch of...
December 22, 2014 01:18 ET | Source: Basilea Pharmaceutica Ltd.

Swissmedic approves Basilea's antibiotic Zevtera(r) (ceftobiprole medocaril) for the treatment of pneumonia

BASEL, Switzerland, Dec. 22, 2014 (GLOBE NEWSWIRE) -- Basilea Pharmaceutica Ltd. (SIX: BSLN) reports that the Swiss regulatory authority Swissmedic has approved the antibiotic Zevtera®...
December 05, 2014 01:21 ET | Source: Basilea Pharmaceutica Ltd.

Basilea announces launch of antibiotic Zevtera(r) (ceftobiprole medocaril) in Germany

First commercial launch BASEL, Switzerland, Dec. 5, 2014 (GLOBE NEWSWIRE) -- Basilea Pharmaceutica Ltd. (SIX: BSLN) announces today that its broad-spectrum antibiotic, Zevtera®...
July 21, 2014 01:22 ET | Source: Basilea Pharmaceutica Ltd.

Basilea to launch Zevtera(r)/Mabelio(r) (ceftobiprole medocaril) in Europe through a commercial services provider

BASEL, Switzerland, July 21, 2014 (GLOBE NEWSWIRE) -- Basilea Pharmaceutica Ltd. (SIX: BSLN) reports that it has entered into an agreement with Quintiles (NYSE: Q) for the commercialization of...